Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XB628 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation Phase | EXPERIMENTAL | Participants with recurrent advanced or metastatic solid tumors will receive escalating dose levels doses of XB628 as a single agent and in combination with zanzalintinib. |
| Dose Expansion | EXPERIMENTAL | Participants with recurrent advanced or metastatic solid tumors will receive XB628 as a single agent and in combination with zanzalintinib. |
| Name | Type | Description |
|---|---|---|
| XB628 | BIOLOGICAL | Intravenous infusion(s) |
| Zanzalintinib | DRUG | Oral tablet(s) |
Key Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. * Minimum life expectancy of ≥ 12 weeks. * Have a recurrent advanced or metastatic solid tumor that is histologically or cytologically confirmed. * Adequate organ and marrow function. * Not amenable to...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
XB628 is an investigational bispecific monoclonal antibody being studied for the treatment of recurrent advanced or metastatic solid tumors, including immune-sensitive tumors. It is currently in Phase 1 clinical development and has not been approved by the FDA.
XB628 targets PD-L1 and NKG2A, making it a bispecific antibody designed to engage two distinct immune checkpoint pathways. By targeting these molecules, it aims to modulate the immune response against tumor cells.
XB628 is being developed by Exelixis, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol EXEL. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy.
XB628 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety, tolerability, and preliminary efficacy.
XB628 is being evaluated in a Phase 1 clinical trial with the identifier NCT06952010. This study is recruiting participants with recurrent advanced or metastatic solid tumors and is testing XB628 both alone and in combination with zanzalintinib. The trial is enrolling approximately 303 participants in the United States.
No, XB628 is not the same as zanzalintinib. XB628 is a bispecific monoclonal antibody targeting PD-L1 and NKG2A, while zanzalintinib is a separate investigational drug. In the ongoing clinical trial, XB628 is being studied both alone and in combination with zanzalintinib.